Synmosa Biopharma Valuation
| 4114 Stock | TWD 33.00 0.05 0.15% |
At this time, the company appears to be fairly valued. Synmosa Biopharma has a current Real Value of NT$33.8 per share. The regular price of the company is NT$33.0. Our model measures the value of Synmosa Biopharma from inspecting the company fundamentals such as Operating Margin of 0.09 %, shares outstanding of 327.14 M, and Return On Equity of 0.0894 as well as reviewing its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Synmosa Biopharma's price fluctuation is very steady at this time. Calculation of the real value of Synmosa Biopharma is based on 3 months time horizon. Increasing Synmosa Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Synmosa stock is determined by what a typical buyer is willing to pay for full or partial control of Synmosa Biopharma. Since Synmosa Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Synmosa Stock. However, Synmosa Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 33.0 | Real 33.8 | Hype 33.0 |
The intrinsic value of Synmosa Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Synmosa Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Synmosa Biopharma helps investors to forecast how Synmosa stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Synmosa Biopharma more accurately as focusing exclusively on Synmosa Biopharma's fundamentals will not take into account other important factors: Synmosa Biopharma Total Value Analysis
Synmosa Biopharma is presently anticipated to have takeover price of 17.93 B with market capitalization of 15.75 B, debt of 2.27 B, and cash on hands of 1.28 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Synmosa Biopharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
17.93 B | 15.75 B | 2.27 B | 1.28 B |
Synmosa Biopharma Investor Information
About 25.0% of the company shares are owned by insiders or employees . The book value of Synmosa Biopharma was presently reported as 15.83. The company last dividend was issued on the 11th of July 2022. Synmosa Biopharma had 1000000:1101600 split on the 9th of August 2024. Based on the key measurements obtained from Synmosa Biopharma's financial statements, Synmosa Biopharma is not in a good financial situation at the moment. It has a very high risk of going through financial straits in February.Synmosa Biopharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Synmosa Biopharma has an asset utilization ratio of 31.36 percent. This indicates that the Company is making NT$0.31 for each dollar of assets. An increasing asset utilization means that Synmosa Biopharma is more efficient with each dollar of assets it utilizes for everyday operations.Synmosa Biopharma Ownership Allocation
Synmosa Biopharma shows a total of 327.14 Million outstanding shares. Synmosa Biopharma maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Synmosa Biopharma Profitability Analysis
The company reported the revenue of 3.23 B. Net Income was 303.86 M with profit before overhead, payroll, taxes, and interest of 1.29 B.About Synmosa Biopharma Valuation
Our relative valuation model uses a comparative analysis of Synmosa Biopharma. We calculate exposure to Synmosa Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Synmosa Biopharma's related companies.Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan. The company was incorporated in 1980 and is based in Taipei, Taiwan. SYNMOSA BIOPHARMA operates under Drug ManufacturersSpecialty Generic classification in Taiwan and is traded on Taiwan OTC Exchange.
8 Steps to conduct Synmosa Biopharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Synmosa Biopharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Synmosa Biopharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Synmosa Biopharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Synmosa Biopharma's revenue streams: Identify Synmosa Biopharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Synmosa Biopharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Synmosa Biopharma's growth potential: Evaluate Synmosa Biopharma's management, business model, and growth potential.
- Determine Synmosa Biopharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Synmosa Biopharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Synmosa Stock Analysis
When running Synmosa Biopharma's price analysis, check to measure Synmosa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synmosa Biopharma is operating at the current time. Most of Synmosa Biopharma's value examination focuses on studying past and present price action to predict the probability of Synmosa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synmosa Biopharma's price. Additionally, you may evaluate how the addition of Synmosa Biopharma to your portfolios can decrease your overall portfolio volatility.